PubMed · 2003 · 28 citations · 0 references
MedicinePharmacologyPharmacotherapyAllergyImmunopharmacologyImmunotherapyAsthma PharmacotherapyAtopic DermatitisInvestigational New Drug ApplicationsMonoclonal Antibody TechnologyAnti-interleukin 5 TherapyAtopic Dermatitis PharmacotherapyEvaluationInterleukin-5 Targeted TherapyMonoclonal Antibody TherapeuticsPhase Ii Clinical Trials
GlaxoSmithKline (formerly SmithKline Beecham) is developing mepolizumab (SB-240563), a monoclonal antibody directed against IL-5, as a potential treatment for asthma and atopic dermatitis. Phase II trials in asthma were underway by April 1998 and by March 2002, phase II trials had also been initiated in atopic dermatitis.